Navigation Links
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Date:5/27/2009

ents include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... Linemeyer , Ph.D., the Company,s Vice President, Biology ... Investor Relations & Corporate Communications, will present an overview ... at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) ...
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract ... will host a complimentary webinar on “Cleaning Validation: Science, ... 4, 2013 at 11 a.m. Eastern Standard Time. ... regulations for cleaning validation. Many companies have incorporated ... evaluation of risk. Some companies have chosen to ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Mass., Sept. 4 Hologic, Inc.,(Nasdaq: HOLX ) ... presenting at the Morgan Stanley Global Healthcare Unplugged,Conference being ... in New,York, NY., Interested parties are invited to ... on Tuesday, September 9, 2008, at 1:35 PM.,Eastern Time ...
... InVitria,( http://www.invitria.com ), a leading ... enhance productivity, safety and time to ... culture, life science research and,diagnostics industry, ... 4th Annual "Optimizing Cell Culture Development" ...
... Second Round of Funding Supports Commercialization of Recently FDA-cleared ... Pathwork(R) Tissue of ... a,molecular diagnostics company focused on oncology, announced the closing,today of ... the heels of FDA,s clearance for the Pathwork(R) Tissue of ...
Cached Biology Technology:Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2Pathwork Diagnostics Closes $20M Financing 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... 2013)The omega 3 fatty acids in fish oil have ... so that the American Heart Association currently recommends eating ... fatty varieties rich in omega 3s. However, the mechanism ... a new study, scientists led by Jason R. Carter ... by providing evidence that fish oil might specifically counteract ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Fish oil may help the heart beat mental stress 2
... are eating their way through our national forests, destroying ... If enforcement efforts to prevent their importation aren,t stepped ... can expect to fork over billions of dollars by ... BioScience . Researchers at the University of ...
... found aboard the RMS Titanic, which is contributing to ... threat to the exterior of ships and underwater metal ... report their findings in the latest issue of the ... published on 8 December, isolated the micro-organisms from a ...
... a feature unique to humans and pets. Scientists at ... brown trout have individual characters and show different personalities. ... at the University of Gothenburg has for many years ... the west coast of Sweden. "My results show ...
Cached Biology News:Ravenous foreign pests threaten national treasures 2New microscopic life aboard the RMS Titanic 2
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... series of media originally developed at the USDA ... the large scale propagation of cells from the ... for the growth and maintenance of cell lines ... in these cell lines. One of the most ...
... The LIC Duet™ GST•Tag™ Ek Adaptor encodes ... ribosome binding site (rbs), ATG translation initation ... The GST•Tag sequence has been reported to ... the solubility of its fusion partners. The ...
... The LIC Duet™ T7•Tag ® Ek ... operator, ribosome binding site (rbs), ATG ... coding sequence. The T7•Tag is a small ... for detection of the target protein with ...
Biology Products: